GLP-1s for Teenagers: the 10 Trials Behind the Approvals (2026)

10 papers · each one re-checked on PubMed · last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Before 2019 a teenager with severe obesity had effectively two pharmacological options, neither good: phentermine, approved only from 16 and only short-term, and metformin used off-label. The door opened in three steps. Liraglutide 1.8 mg reached a pediatric type 2 diabetes label in June 2019 on the strength of ELLIPSE. Liraglutide 3.0 mg reached an adolescent weight label in December 2020 after SCALE Teens. Semaglutide 2.4 mg followed in December 2022 for ages 12 and up after STEP TEENS. Tirzepatide has trials running and no pediatric label as of 2026. Two of the ten papers below are not GLP-1 trials at all. They are the Teen-LABS bariatric surgery cohorts, included because surgery is the comparator in any conversation about a severely affected teenager. The trade on offer is comparable, durable weight loss without surgery, in exchange for staying on a drug indefinitely.

Ranked papers

#1STEP TEENS

Once-Weekly Semaglutide in Adolescents with Obesity

Weghuber D, Barrett T, Barrientos-Pérez M, et al. · N Engl J Med · 2022

What it measured: Change in BMI over 68 weeks in adolescents

The trial behind the approval: 201 teenagers aged 12 to 17 with obesity, given weekly semaglutide 2.4 mg or a placebo across 68 weeks, with lifestyle support in both arms. BMI fell 16.1% on the drug while rising 0.6% on placebo, and 73% of the treated group shed 5% or more of their body weight against 18% on placebo. It produced the December 2022 pediatric label for Wegovy.

PMID 36322838 ↗NCT04102189 ↗DOI 10.1056/NEJMoa2208601 ↗

#2SCALE Teens

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

Kelly AS, Auerbach P, Barrientos-Perez M, et al. · N Engl J Med · 2020

What it measured: Change in BMI relative to peers of the same age and sex, at 56 weeks

The trial that opened adolescent weight management to this class. It gave 251 teenagers for whom lifestyle therapy had not worked daily liraglutide 3.0 mg or a placebo across 56 weeks, then followed them for a further 26 weeks off the drug. BMI standard-deviation score fell 0.22 more than placebo and weight 4.5 kg more. The off-treatment phase is the part to remember: once the drug stopped, BMI standard-deviation score rose more in the liraglutide group than on placebo. It is the same rebound adult trials document, in patients who may face sixty more years of it.

PMID 32233338 ↗NCT02918279 ↗DOI 10.1056/NEJMoa1916038 ↗

#3ELLIPSE

Liraglutide in Children and Adolescents with Type 2 Diabetes

Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. · N Engl J Med · 2019

What it measured: Change in glycated hemoglobin at 26 weeks

The first pediatric label in the class, and the template for everything after it. Liraglutide 1.8 mg daily went up against placebo over 26 weeks, plus a 26-week extension, in 134 patients aged 10 to 16 whose diabetes metformin had failed to control. A1C fell 0.64 points on the drug and rose 0.42 on placebo, a gap of 1.06 points. It produced the June 2019 Victoza pediatric indication and established that a pediatric program in this class could succeed.

PMID 31034184 ↗NCT01541215 ↗DOI 10.1056/NEJMoa1903822 ↗

#4STEP TEENS (post-hoc)

Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg

Kelly AS, Arslanian S, Hesse D, et al. · Obesity (Silver Spring) · 2023

What it measured: How many teenagers dropped below the obesity and overweight cutoffs

A secondary analysis of STEP TEENS that reframed the result in terms a parent or a prior-authorization reviewer can act on. Rather than reporting BMI points, it counted how many teenagers crossed diagnostic lines: by week 68, 45% on semaglutide had dropped below the obesity threshold against 12% on placebo, and 74% had moved down at least one BMI category against 19%. That framing, moving out of a category rather than shaving a number, is what pediatric prescribing guidance now leans on.

PMID 37196421 ↗NCT04102189 ↗DOI 10.1002/oby.23808 ↗

#5BCB114

Once-Weekly Exenatide in Youth With Type 2 Diabetes

Tamborlane WV, Bishai R, Geller D, et al. · Diabetes Care · 2022

What it measured: Change in glycated hemoglobin at 24 weeks

Weekly exenatide 2 mg against placebo across 24 weeks in 83 patients aged 10 to 17, their diabetes managed by diet, metformin or long-acting insulin. A1C fell 0.36 points and rose 0.49 on placebo, a gap of 0.85. Its contribution is less the effect size than the format: it demonstrated that a once-weekly injection is workable in this age group, and it added a second GLP-1 drug to a pediatric toolkit that had exactly one, daily liraglutide.

PMID 35679098 ↗NCT01554618 ↗DOI 10.2337/dc21-2275 ↗

#6

Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial

Mastrandrea LD, Witten L, Carlsson Petri KC, et al. · Pediatr Obes · 2019

What it measured: Whether children aged 7 to 11 tolerated the drug, and what blood levels resulted

An early randomized GLP-1 study in children under 12: 24 children aged 7 to 11 with obesity, given placebo or liraglutide titrated up to 3.0 mg, for five weeks. It was a phase 1 study of safety, tolerability and drug levels, not weight. Gastrointestinal effects dominated (37.5% against 12.5% on placebo), and exposure rose in proportion to dose. BMI Z-score did fall slightly more than on placebo (a difference of 0.28). With twenty-four children over five weeks, it is a dosing study that informs future trials, not evidence about treating children this age.

PMID 30653847 ↗DOI 10.1111/ijpo.12495 ↗

#7Teen-LABS

Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents

Inge TH, Courcoulas AP, Jenkins TM, et al. · N Engl J Med · 2016

What it measured: Weight three years after bariatric surgery in adolescents

The comparator, not a drug trial. 242 teenagers aged 13 to 19 tracked prospectively after undergoing gastric bypass or a sleeve procedure for severe obesity. At three years weight was down 27%, with type 2 diabetes remitting in 95%, hypertension in 74% and dyslipidemia in 66%. This was the standard of care for severe adolescent obesity before these drugs existed, and it is the benchmark a 16% BMI reduction gets weighed against.

PMID 26544725 ↗NCT00474318 ↗DOI 10.1056/NEJMoa1506699 ↗

#8Teen-LABS / LABS-2

Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults

Inge TH, Courcoulas AP, Jenkins TM, et al. · N Engl J Med · 2019

What it measured: Weight five years after gastric bypass, adolescents against adults

The follow-on comparison that made the case for operating earlier: 161 adolescents from Teen-LABS matched against 396 adults five years after the same procedure. Weight loss was similar (26% against 29%), but the metabolic recovery was not. Type 2 diabetes remitted in 86% of adolescents against 53% of adults, and hypertension in 68% against 41%. It is the strongest argument that metabolic disease is more reversible the earlier it is treated, which cuts both ways in the drug conversation.

PMID 31116917 ↗NCT00474318 ↗DOI 10.1056/NEJMoa1813909 ↗

#9

Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents with obesity: A systematic review and meta-analysis

Sedenho-Prado LG, Yugar LBT, Whitaker AR, et al. · Int J Obes (Lond) · 2025

What it measured: BMI and weight pooled across the randomized pediatric trials

Pooled randomized evidence from eight trials and 715 children and adolescents with obesity. BMI, weight, waist circumference and systolic blood pressure fell more than on placebo (a standardized mean difference of −0.67 for BMI), while lipids, A1C and fasting glucose did not change and heart rate rose slightly. Nausea and vomiting were the dominant tolerability finding, though few participants withdrew.

PMID 40269110 ↗DOI 10.1038/s41366-025-01790-w ↗

#10

GLP-1 receptor agonists for the treatment of obesity in children and adolescents: a meta-analysis of randomized controlled trials

Romariz LM, de Melo AAC, Finnegan E, et al. · Pediatr Res · 2026

What it measured: BMI z-score, weight and waist circumference, pooled across trials

The 2026 update: 11 randomized trials and 1,024 patients aged 6 to 19. Against placebo, GLP-1 drugs cut weight by 4.32 kg, BMI z-score by 0.28 and waist circumference by 3.84 cm, with gastrointestinal symptoms the most common adverse event. Its distinctive contribution is a separate analysis of children under 12, where BMI z-score also fell (by 0.33), which the authors read as a sign that younger children may benefit too.

PMID 40588554 ↗DOI 10.1038/s41390-025-04228-1 ↗

About this list

Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-11-07 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.

Browse our full index of research lists or our long-form research articles.